Market Overview

Benzinga's Top Pre-Market Losers

Related HALO
Halozyme Therapeutics Beats Q4 Views; Outlook Shy Of Consensus
Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2
Halozyme Q4 Loss Narrower-than-Expected, Revenues Up - Analyst Blog (Zacks)
Related ENTR
MaxLinear and Entropic Announce Early Termination of Hart-Scott-Rodino Waiting Period for MaxLinear's Pending Acquisition of Entropic
MaxLinear Gains On Merger Deal With Entropic Communications
Why You Shouldn't Bet Against Entropic Communications (ENTR) Stock - Tale of the Tape (Zacks)

Halozyme Therapeutics (NASDAQ: HALO) dipped 20.68% to $6.75 in the pre-market session after the company provided update on ViroPharma Phase 2 study of subcutaneous Cinryze (C1 Esterase Inhibitor [Human]) with recombinant human hyaluronidase.

Entropic Communications (NASDAQ: ENTR) shares fell 16.48% to $3.70 in the pre-market trading after the company reported Q2 results. Benchmark downgraded Entropic from “buy” to “hold.”

Reliv International (NASDAQ: RELV) shares dropped 15.57% to $3.09 in pre-market trading after the company posted a Q2 net loss of $214,000, versus a year-ago net income of $103,000.

NII Holdings (NASDAQ: NIHD) dipped 6.94% to $6.70 in the pre-market session on second-quarter results.

Posted-In: Top Pre-Market LosersNews Movers & Shakers Pre-Market Outlook Markets


Related Articles (ENTR + HALO)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→